EASD 2026 28 September - 2 October 2026

Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability

Authors :

Rune Viig Overgaard¹; Mathilde Guldbæk Arentsen¹; Andrei-Mircea Catarig¹; Filipe Cortes-Figueiredo¹; Paula Freitas²; Jan-Otto Hooghoudt¹; Anders Strathe¹; Minh Chau Tran¹; Nikolaos Tentolouris³

Affiliations

View Details Hide Details

Download the poster (.pdf)

Keywords

Diabetes

Congress short oral presentation

GLP-1 RA

Semaglutide

Clinical

Search Science Hub

Are you a healthcare professional?

Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability